Processing
Collecting data for MSTX

Mast price prediction

$0.48  0.01  2.04%
    
  
Summary
PerformanceFundamentalsTechnicalsRecomendation
   Summary
   History
   Headlines
   Leaders
   Widgets
Investment horizon:  
  30 Days    Login   to change
With this exotic module your can estimate the sentimental value of Mast Therapeutics Inc from the prospective of Mast response to recently generated media hype and the effects of current headlines on its competitors. The module also provides analysis of price elasticity to changes in media outlook on Mast over a specific investment horizon. See also Mast Backtesting, Mast Volatility, Mast Valuation, Mast Correlation, Mast History and Mast Performance

Mast hype analysis

Daily Expected returnPeriod VolatilityHype elasticityRelated hype elasticityAverage news densityRelated news densityNext Expected Hype
Price Moved Down 0.32% 2.49%No Change 0.00% Price Moved Up 0.84% 1 Events / Month2 Events / MonthUncertain
Latest traded priceExpected after-news pricePotential return on next major newsAverage after-hype volatility
0.48
0.48
0.00%
24,900% 

Mast estimiated after-hype price volatility

Next price density
 
Embed  
Expected price to next headline
July 3, 2015
0.48
Current Value
Downside upside
Downside
0.02
0.48
After-hype Price
7.95
Upside
Upside upside
Mast is abnormally risky asset. Analysis and calculation of next after-hype price of Mast Therapeutics is based on 1 month time horizon.

Mast hype timeline

Mast Therapeutics Inc is now traded for 0.48 . This company stock is not elastic to its hype. The average elasticity to hype of competition is 0.84. Mast Therapeutics Inc is projected not to react to the next headline with price going to stay at about the same level and average media hype impact volatility of 24900.0%. The immediate return on the next news is projected to be very small where as daily expected return is now at -0.32%. The volatility of relative hype elasticity to Mast is about 94.71%%. The volatility of related hype on Mast is about 94.71% with expected price after next announcement by competition of 1.32. About 20.0% of the company shares are owned by institutional investors. The company has price-to-book ratio of 1.59. Typically companies with comparable Price to Book (P/B) are able to outperform the market in the long run. Mast Therapeutics Inc recorded loss per share of 0.24. This company had not issued any dividends in recent years. The firm had 1:25 split on April 26, 2010. Given the investment horizon of 30 days, the next projected press release will be uncertain.
See also Mast Backtesting, Mast Volatility, Mast Valuation, Mast Correlation, Mast History and Mast Performance
Mast Value 
Benchmark  Embed   Timeline 

Mast related hype analysis

Hype
Elasticity
News
Dencity
Semi
Deviation
Information
Ratio
Expected
Short fall
Potential
Upside
Value
At Risk
Maximum
Drawdown
Gilead Sciences Inc 0.80 2 per month 0.00  0.08  0.00  1.96 (1.46) 5.93 
Amgen Inc 3.79 2 per month 0.00 (0.06) 0.00  1.55 (1.16) 6.93 
Biogen Idec Inc 1.69 2 per month 0.00  0.22  0.00  2.37 (1.35) 5.80 
Celgene Corporation 1.18 1 per month 0.00  0.29  0.00  2.14 (1.46) 6.80 
Regeneron Pharmaceuticals Inc 11.13 2 per month 0.00  0.02  0.00  2.94 (2.62) 7.01 
Alexion Pharmaceuticals Inc 2.36 2 per month 0.00  0.37  0.00  2.47 (3.11) 10.44 
Vertex Pharmaceuticals Incorporated 4.24 1 per month 0.00  0.13  0.00  2.89 (1.57) 6.71 
Illumina Inc(1.23)3 per month 0.00  0.32  0.00  2.05 (1.17) 4.21 
BioMarin Pharmaceutical Inc 1.35 2 per month 0.00  0.23  0.00  3.38 (1.88) 14.06 
Incyte Corporation 0.98 2 per month 0.00  0.0083  0.00  3.33 (3.10) 7.01